Nicolas Berg, Redalpine Venture Partners, Journalist BR
Nicolas Berg, Redalpine Venture Partners, Journalist BR
Contact:
Oliver Rinner, co-founder and CSO
Phone:
E-Mail: rinner@biognosys.ch
KEYWORDS:

[ Download Photos ]

SCIENCE
Fri, 25.03.2011
Print
pts20110325029 Health/Medicine, Products/Innovations
Pressbox Pressbox
Biognosys Brings Proteomic Breakthroughs to Mainstream Users
Software Platform Extends Targeted Proteomics Beyond Expert Labs
Oliver Rinner, Proteomics Pioneer
Oliver Rinner, Proteomics Pioneer
[ photos ]

Zurich (pts029/25.03.2011/21:51) - Biognosys, a leading provider of targeted proteomics solutions, announces the software platform mProphet for large-scale applications in industrial and academic research. The software was recently published in "Nature Methods": With the new tool researchers can analyze complex proteomics data and generate statistically validated results.

The advancement is mProphet, a software package created by scientists from the Institute of Molecular Systems Biology at ETH Zurich and Biognosys Ltd, a leading provider of proteomics solutions to biology research partners. The software offers automated, standardized analysis of data gathered in multiple reaction monitoring mass spectrometry (MRM), or Targeted Proteomics.

A prominent leader in proteomics, Dr. Ruedi Aebersold, shared, "The development of the mProphet software tool is highly significant for the emerging field of targeted proteomics because it will allow users to generate statistically validated data sets right from the outset." Historically, researchers struggled to objectively analyze expansive, complex proteomics data. "The mProphet tool will avoid this pitfall for targeted proteomics and make data generated in different laboratories directly comparable. This matches last year's Human Proteome Organization (HUPO) conference where the development of MRM assays for the whole human proteome was announced. Now we have everything in hand to broadly apply MRM proteomics".

The publication further highlights the software's ability to increase protein target sensitivity in MRM proteomics across a range of organisms. "An ability that once only existed among a particular group of scientists is becoming broadly available for industrial, academic, and clinical organizations. This technology will increasingly be used in drug discovery, diagnostics, gene expression, crop science, metabolic research - basically any field related to proteins in any living organism", said Dr. Oliver Rinner, CSO at Biognosys AG.
The software is already being used by academic laboratories and Biognosys. More information can be found at http://www.mprophet.org.

Articles and media releases
"Nature" article on mProphet can be found on Nature's website:
http://www.nature.com/nmeth/journal/vaop/ncurrent/full/nmeth.1584.html

Biognosys' press release announcing complete sequencing of human proteome at HUOP 2010:
http://www.newsfox.com/pte.mc?pte=100923038

About Biognosys
Originally spun-off from ETH in 2008, Biognosys began by providing targeted proteomics technology to identify and quantify proteins for some leading companies in pharmaceutics, diagnostics and healthcare. Since then, Biognosys has expanded their scope to include biotechnology and agricultural customers, offering contract research services, laboratory materials, and proprietary technology used in mass spectrometry.

Contact
Biognosys AG, Wagistrasse 25, CH-8952 Zurich-Schlieren, Switzerland, http://www.biognosys.ch

(end)
Submitter: Nicolas Berg, Redalpine Venture Partners, Journalist BR
Contact: Oliver Rinner, co-founder and CSO
Phone:
E-Mail: rinner@biognosys.ch
Website:
Nicolas Berg, Redalpine Venture Partners, Journalist BR